Microbial DNA, ribosomes, and metabolic enzymes

Microbial DNA, ribosomes, and metabolic enzymes represent a broad aggregate of essential cellular components that serve as the primary targets for most antimicrobial therapies. Microbial DNA is targeted by fluoroquinolones, which inhibit the enzymes DNA gyrase and topoisomerase IV, and by nitroimidazoles, which cause direct DNA strand breakage (PubMed: PMC4957381). The microbial ribosome, specifically the 30S and 50S subunits, is the site of action for numerous antibiotic classes—including aminoglycosides, tetracyclines, and macrolides—which exploit structural differences between prokaryotic and eukaryotic ribosomes to selectively inhibit protein synthesis (Nature Reviews Microbiology, 2014). Metabolic enzymes, particularly those involved in the folic acid synthesis pathway like dihydropteroate synthase, are targeted by sulfonamides to starve the pathogen of precursors necessary for nucleic acid synthesis. Because this entry combines multiple distinct molecular targets (nucleic acids, large ribonucleoprotein complexes, and various protein enzymes) into a single category, it is considered a composite classification rather than a specific therapeutic target. This diversity of targets is critical for combination therapies designed to overcome resistance and broaden the spectrum of activity against various bacterial, fungal, and protozoal infections.

Other names

Bacterial cellular machineryAntimicrobial targetsProkaryotic molecular targetsMicrobial biosynthetic pathways

Drugs targeting these components act by inhibiting DNA gyrase and topoisomerase IV to prevent replication, binding to the 30S or 50S ribosomal subunits to arrest protein synthesis, or competitively inhibiting enzymes like dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) to disrupt essential metabolic pathways such as folate synthesis (StatPearls: Antibiotics, 2023).